Modifiable barriers for recruitment and retention of older adults participants from underrepresented minorities in alzheimer's disease research
Open accessThe DOI matches its Crossref record; 100 of the 101 references it cites were found in a registry or an index.
Abstract
Clinical Alzheimer’s disease (AD) trials currently face a critical shortfall of thousands of eligible participants, which inflates the duration and cost of the clinical study as well as threatens the scientific merit of promising clinical interventions. This recruitment crisis is further compounded by the fact that underrepresented and marginalized populations—particularly those identifying as a racial or ethnic minority, those with low socioeconomic status, or living in rural areas—have been historically underrepresented in ongoing AD clinical trials despite overwhelming evidence that such populations are at increased risk for developing dementia. As a result of various recruitment barriers, current AD clinical studies frequently reflect a decreasingly representative segment of the US population, which threatens the overall generalizability of these findings. The current narrative review provides an updated examination and critique of common recruitment barriers and potential solutions, as well as a discussion of theoretical approaches that may address barriers disproportionately experienced by underrepresented communities. AD clinical researchers are encouraged to take purposive action aimed at increasing diversity of enrolled AD clinical trial cohorts by actively identifying and quantifying barriers to research participation—especially recruitment barriers and health disparities that disproportionately prevent underrepresented and marginalized populations from participating in research. Furthermore, researchers are encouraged to closely track which individuals who express interest in AD research ultimately enroll in research studies to examine whether AD research participation is appropriately representative of the intended population for whom these new and novel AD interventions are being designed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
EFFECTIVE RECRUITMENT AND RETENTION OF MINORITY RESEARCH PARTICIPANTS
Yancey, A. K., Ortega, A. N., & Kumanyika, S. K. (2006) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.27.021405.102113 · Cited by 1,196 · cited 1×
“questions to staff members [32, 63] stagger and reit-”
Background2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
Thies, W., & Bleiler, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 982
Increasing Diversity in Clinical Trials: Overcoming Critical Barriers
Clark, L. T., Watkins, L., Piña, I. L., Elmer, M., Akinboboye, O., Gorham, M., Jamerson, B., McCullough, C., Pierre, C., Polis, A. B., et al. (2019) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2018.11.002 · Cited by 731 · cited 5×
“Clinical researchers must also prioritize patient health and safety by frequently monitoring their physical and psychological health and promptly addressing any side-effects experienced by the patient [71].”
BackgroundInfluentialCrocker, J. C., Ricci-Cabello, I., Parker, A., Hirst, J. A., Chant, A., Petit-Zeman, S., Evans, D., & Rees, S. (2018) · BMJ · doi:10.1136/bmj.k4738 · Cited by 624 · cited 1×
“Difficulty in participant recruitment runs the risk of delaying treatment delivery [108] by inflating the duration and cost of the clinical study [6, 108] and has the potential to threaten the external validity of research findings [108].”
BackgroundBabulal, G. M., Quiroz, Y. T., Albensi, B. C., Arenaza‐Urquijo, E., Astell, A. J., Babiloni, C., Bahar‐Fuchs, A., Bell, J., Bowman, G. L., Brickman, A. M., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.09.009 · Cited by 528 · cited 7×
“Existing research has also demonstrated a difference in AD pathophysiology between African American and Caucasian populations, which may unwittingly result in underdiagnosis of AD among African Americans [91, 92].”
BackgroundInfluentialThe effect of informal care on work and wages
Van Houtven, C. H., Coe, N. B., & Skira, M. M. (2013) · Journal of Health Economics · doi:10.1016/j.jhealeco.2012.10.006 · Cited by 479 · cited 4×
“Caregivers lacking favorable attitudes towards research, fear of potential side-effects, and wish to avoid increasing patient’s burden [9, 10, 66] Provide frequent opportunities to ask clarifying questions [67, 73]; frequent opportunities to discuss risk and benefits of research participation [65]”
BackgroundInfluentialAssessment of Racial Disparities in Biomarkers for Alzheimer Disease
Morris, J. C., Schindler, S. E., McCue, L. M., Moulder, K. L., Benzinger, T. L. S., Cruchaga, C., Fagan, A. M., Grant, E., Gordon, B. A., Holtzman, D. M., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4249 · Cited by 370 · cited 5×
“Community-based providers being unaware of ongoing AD clinical trials [2]; lack of communication between community providers and researchers [74]; absence of formal training for referring providers [65]; time constraints experienced by community-based medical providers [78]; fear of losing patients to medical research…”
BackgroundResultInfluentialMody, L., Miller, D. K., McGloin, J. M., Freeman, M., Marcantonio, E. R., Magaziner, J., & Studenski, S. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2008.02015.x · Cited by 361 · cited 1×
“Such barriers include 1) medical and/or psychiatric disturbances [2, 31] that may increase heterogeneity in participant response to the treatment protocol and are therefore often identified as exclusionary criteria in ongoing AD research [39], 2) need for a study partner [2], 3) participant burden [40], 4) unique barr…”
BackgroundAlzheimer’s Disease In African Americans: Risk Factors And Challenges For The Future
Barnes, L. L., & Bennett, D. A. (2014) · Health Affairs · doi:10.1377/hlthaff.2013.1353 · Cited by 353
Landry, L. G., Ali, N., Williams, D. R., Rehm, H. L., & Bonham, V. L. (2018) · Health Affairs · doi:10.1377/hlthaff.2017.1595 · Cited by 344
Racial/ethnic differences in drug disposition and response: Review of recently approved drugs
Ramamoorthy, A., Pacanowski, M., Bull, J., & Zhang, L. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.61 · Cited by 341
Literacy and Memory Decline Among Ethnically Diverse Elders
Manly, J. J., Touradji, P., Tang, M.-X., & Stern, Y. (2003) · Journal of Clinical and Experimental Neuropsychology · doi:10.1076/jcen.25.5.680.14579 · Cited by 329
Threats to Applicability of Randomised Trials: Exclusions and Selective Participation
Britton, A., McKee, M., Black, N., McPherson, K., Sanderson, C., & Bain, C. (1999) · Journal of Health Services Research & Policy · doi:10.1177/135581969900400210 · Cited by 299 · cited 2×
“Such bias may in turn cast uncertainty about the extrapolation of their findings to a more general population [45].”
BackgroundGilmore‐Bykovskyi, A. L., Jin, Y., Gleason, C., Flowers‐Benton, S., Block, L. M., Dilworth‐Anderson, P., Barnes, L. L., Shah, M. N., & Zuelsdorff, M. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.09.018 · Cited by 295 · cited 9×
“Additionally, positive views about the trial brought on by psychoeducation around the patient’s potential to directly benefit from participation [61, 62, 67], learn more about their clinical condition [62], and advance AD research [9, 62] may help mitigate some potential burden associated with enrolling in clinical tr…”
BackgroundInfluentialP1‐071: Intensity of dementia through latent variable modelling (I‐DeLV) in the AIBL cohort
Burnham, S., Graham, P., Wilson, B., Ames, D., Macaulay, L., Martins, R., Masters, C., Maruff, P., Rowe, C., Szoeke, C., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.05.347 · Cited by 292
Heller, C., Balls-Berry, J. E., Nery, J. D., Erwin, P. J., Littleton, D., Kim, M., & Kuo, W. P. (2014) · Contemporary Clinical Trials · doi:10.1016/j.cct.2014.08.004 · Cited by 290 · cited 9×
“Potential efforts to mitigate these barriers may include direct outreach through in-person meetings with medical providers at primary care clinics [81–84] in an effort to provide detailed information about the study, address any concerns identified by the provider [69, 73], and communicate ongoing progress of the stud…”
BackgroundInfluentialSisco, S., Gross, A. L., Shih, R. A., Sachs, B. C., Glymour, M. M., Bangen, K. J., Benitez, A., Skinner, J., Schneider, B. C., & Manly, J. J. (2015) · The Journals of Gerontology Series B: Psychological Sciences and Social Sciences · doi:10.1093/geronb/gbt133 · Cited by 277
Ortega, V. E., & Meyers, D. A. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.10.040 · Cited by 237
Cognitive test performance among nondemented elderly African Americans and whites
Manly, J. J., Jacobs, D. M., Sano, M., Bell, K., Merchant, C. A., Small, S. A., & Stern, Y. (1998) · Neurology · doi:10.1212/wnl.50.5.1238 · Cited by 231
Reviews: Developing Culturally Sensitive Dementia Caregiver Interventions: Are We There Yet?
Napoles, A. M., Chadiha, L., Eversley, R., & Moreno-John, G. (2010) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317510370957 · Cited by 224
Obstacles and opportunities in Alzheimer’s clinical trial recruitment
Watson, J. L., Ryan, L., Silverberg, N., Cahan, V., & Bernard, M. A. (2014) · Health Affairs · doi:10.1377/hlthaff.2013.1314 · Cited by 204 · cited 7×
“For example, AD clinical trials focused on disease prevention seek to recruit cognitively intact participants who are at higher risk of AD as identified by genetic and biomarker studies [2, 6, 48].”
BackgroundInfluentialHowell, J. C., Watts, K. D., Parker, M. W., Wu, J., Kollhoff, A., Wingo, T. S., Dorbin, C. D., Qiu, D., & Hu, W. T. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0315-1 · Cited by 198 · cited 6×
“Community-based providers being unaware of ongoing AD clinical trials [2]; lack of communication between community providers and researchers [74]; absence of formal training for referring providers [65]; time constraints experienced by community-based medical providers [78]; fear of losing patients to medical research…”
BackgroundResultInfluentialGrill, J. D., & Karlawish, J. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt58 · Cited by 198 · cited 2×
“AD clinical trials have historically focused on recruiting spouses as study partners [2, 30, 58].”
BackgroundTaylor, J. S., DeMers, S. M., Vig, E. K., & Borson, S. (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03847.x · Cited by 192 · cited 1×
“For example, past research has found that cognitive impairment is frequently used as an exclusion criteria in geriatric research; however, a majority of such research offered no rationale in support of using such exclusion criteria [42, 46].”
BackgroundGetting to the Heart of Alzheimer Disease
Tublin, J. M., Adelstein, J. M., del Monte, F., Combs, C. K., & Wold, L. E. (2019) · Circulation Research · doi:10.1161/circresaha.118.313563 · Cited by 188 · cited 1×
“The abovementioned statistic is also especially concerning in light of the evidence that CVD is frequently associated with AD [47, 51] and a significant proportion of AD patients present with vascular abnormalities [47].”
BackgroundAreán, P. A., & Gallagher-Thompson, D. (1996) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.64.5.875 · Cited by 178
Elting, L. S., Cooksley, C., Bekele, B. N., Frumovitz, M., Avritscher, E. B. C., Sun, C., & Bodurka, D. C. (2006) · Cancer · doi:10.1002/cncr.21907 · Cited by 176
A Review and Assessment of Potential Sources of Ethnic Differences in Drug Responsiveness
Bjornsson, T. D., Wagner, J. A., Donahue, S. R., Harper, D., Karim, A., Khouri, M. S., Murphy, W. R., Roman, K., Schneck, D., Sonnichsen, D. S., et al. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003256065 · Cited by 143
Turner, A. D., James, B. D., Capuano, A. W., Aggarwal, N. T., & Barnes, L. L. (2017) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.10.003 · Cited by 136
Vega, I. E., Cabrera, L. Y., Wygant, C. M., Velez-Ortiz, D., & Counts, S. E. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161261 · Cited by 135
Eligibility of Alzheimer's Disease Clinic Patients for Clinical Trials
Schneider, L. S., Olin, J. T., Lyness, S. A., & Chui, H. C. (1997) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1997.tb02960.x · Cited by 132 · cited 1×
“Hence, the use of vascular comorbidities as exclusion criteria disproportionately excludes African Americans from ongoing AD clinical research in comparison to their non-Hispanic White counterparts [42, 50].”
BackgroundFargo, K. N., Carrillo, M. C., Weiner, M. W., Potter, W. Z., & Khachaturian, Z. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.10.001 · Cited by 123 · cited 4×
“For example, AD clinical trials focused on disease prevention seek to recruit cognitively intact participants who are at higher risk of AD as identified by genetic and biomarker studies [2, 6, 48].”
BackgroundInfluentialConnell, C. M., Shaw, B. A., Holmes, S. B., & Foster, N. L. (2001) · Alzheimer Disease and Associated Disorders · doi:10.1097/00002093-200107000-00005 · Cited by 118 · cited 1×
“questions to staff members [32, 63] stagger and reit-”
BackgroundRecruitment of a Community-based Cohort for Research on Diversity and Risk of Dementia
Hinton, L., Carter, K., Reed, B. R., Beckett, L., Lara, E., DeCarli, C., & Mungas, D. (2010) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181c1ee01 · Cited by 116
ALS clinical trials: Do enrolled patients accurately represent the ALS population?
Chiò, A., Canosa, A., Gallo, S., Cammarosano, S., Moglia, C., Fuda, G., Calvo, A., Gabriele, M., & For the PARALS group (2011) · Neurology · doi:10.1212/wnl.0b013e318232ab9b · Cited by 114
Facilitating Alzheimer Disease Research Recruitment
Grill, J. D., & Galvin, J. E. (2014) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000016 · Cited by 114 · cited 5×
“AD clinical research frequently uses comorbid medical conditions (such as cardiovascular disease) [47] and psychiatric disorders as exclusion criteria [31].”
BackgroundInfluentialEvelyn, B., Toigo, T., Banks, D., Pohl, D. J., Gray, K., Robins, B., & Ernat, J. J. (2001) · PubMed Central · Cited by 105
African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials
Zhou, Y., Elashoff, D., Kremen, S., Teng, E., Karlawish, J., & Grill, J. D. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.09.004 · Cited by 95
Gleason, C. E., Norton, D., Zuelsdorff, M., Benton, S. F., Wyman, M. F., Nystrom, N., Lambrou, N., Salazar, H., Koscik, R. L., Jonaitis, E., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.07.015 · Cited by 95 · cited 1×
“[107] demonstrated that recruitment bias confounds”
Warner, E. T., Glasgow, R. E., Emmons, K. M., Bennett, G. G., Askew, S., ROSNER, B. A., & Colditz, G. A. (2013) · BMC Public Health · doi:10.1186/1471-2458-13-192 · Cited by 93
Understanding What Information Is Valued By Research Participants, And Why
Wilkins, C. H., Mapes, B. M., Jerome, R. N., Villalta-Gil, V., Pulley, J. M., & Harris, P. A. (2019) · Health Affairs · doi:10.1377/hlthaff.2018.05046 · Cited by 92 · cited 3×
“Unique barriers preventing participation such as mistrust [9, 75, 98]; fear of exploitation [75, 98]; history of racism in research [9, 99]; cultural beliefs surrounding illness [96] as well as medical procedures [98, 99] Establishing rapport with members of diverse communities [98]; Engaging potential research partic…”
BackgroundRecruitment and Retention of Elderly Patients in Clinical Trials: Issues and Strategies
Cassidy‐Eagle, E. L., Baird, E., & Sheikh, J. I. (2001) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200105000-00005 · Cited by 90
How do AD patients and their caregivers decide whether to enroll in a clinical trial?
Karlawish, J. H., Casarett, D., Klocinski, J., & Sankar, P. L. (2001) · Neurology · doi:10.1212/wnl.56.6.789 · Cited by 88
Elliott, C. L. (2020) · Ethnicity & Disease · doi:10.18865/ed.30.s2.705 · Cited by 85
Brain Behavior Relationships Among African Americans, Whites, and Hispanics
DeCarli, C., Reed, B. R., Jagust, W., Martinez, O., Ortega, M., & Mungas, D. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318185e7fe · Cited by 84 · cited 4×
“Racial minorities such as African Americans and Hispanics have been found to have a higher risk of developing AD in comparison to their Caucasian counterparts [8–10], and yet these populations are historically underrepresented in AD clinical research [9, 10].”
BackgroundInfluentialFaison, W. E., Schultz, S. K., Aerssens, J., Alvidrez, J., Anand, R., Farrer, L. A., Jarvik, L., Manly, J., McRae, T., Murphy, G. M., et al. (2007) · International Psychogeriatrics · doi:10.1017/s104161020700511x · Cited by 76
Abner, E. L., Jicha, G. A., Christian, W. J., & Schreurs, B. G. (2016) · The Journal of Rural Health · doi:10.1111/jrh.12155 · Cited by 75
Chan, C. C., Fage, B. A., Burton, J. K., Smailagic, N., Gill, S. S., Herrmann, N., Nikolaou, V., Quinn, T. J., Noel-Storr, A. H., & Seitz, D. P. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011414.pub2 · Cited by 73
Jefferson, A. L., Lambe, S., Chaisson, C., Palmisano, J., Horvath, K. J., & Karlawish, J. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101536 · Cited by 72 · cited 6×
“Additionally, positive views about the trial brought on by psychoeducation around the patient’s potential to directly benefit from participation [61, 62, 67], learn more about their clinical condition [62], and advance AD research [9, 62] may help mitigate some potential burden associated with enrolling in clinical tr…”
BackgroundInfluentialSeitz, D. P., Chan, C. C., Newton, H. T., Gill, S. S., Herrmann, N., Smailagic, N., Nikolaou, V., & Fage, B. A. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011415.pub2 · Cited by 70
Effect of study partner on the conduct of Alzheimer disease clinical trials
Grill, J. D., Raman, R., Ernstrom, K., Aisen, P., & Karlawish, J. (2013) · Neurology · doi:10.1212/wnl.0b013e31827debfe · Cited by 69 · cited 2×
“As a result, approximately two-thirds of study partners enrolled in AD research are often spouses [2, 10, 59].”
BackgroundCooper, C., Ketley, D., & Livingston, G. (2014) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4034 · Cited by 65
A Road Map for the Recruitment and Retention of Older Adult Participants for Longitudinal Studies
Bonk, J. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2010.02937.x · Cited by 58 · cited 3×
“Participation by underrepresented populations Lack of adequate representation by ethnically/racially diverse populations [9, 54, 93–95], socially diverse populations [9], and rural populations [9] Appealing to racially-ethnically diverse participants currently enrolled in ongoing research [40]; increasing referral fro…”
BackgroundHumphreys, K., Weingardt, K. R., Horst, D., Joshi, A. A., & Finney, J. W. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01175.x · Cited by 57
TRIVEDI, R. B., & Humphreys, K. N. (2015) · Contemporary Clinical Trials · doi:10.1016/j.cct.2015.07.009 · Cited by 57
African American Participation in Alzheimer’s Disease Research That Includes Brain Donation
Darnell, K. R., McGuire, C., & Danner, D. D. (2011) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317511423020 · Cited by 52 · cited 6×
“aimed as delaying disease onset or progression [93].”
BackgroundInfluentialStudy partners: essential collaborators in discovering treatments for Alzheimer’s disease
Largent, E. A., Karlawish, J. H., & Grill, J. D. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0425-4 · Cited by 51 · cited 10×
“Family members may discourage a patient from participating in clinical trials if they question the effectiveness of the intervention or wish to avoid increasing the patient’s medical burden [10] resulting from greater frequency of medical appointments.”
BackgroundInfluentialEffective Recruitment and Retention Strategies for Older Members of Rural Minorities
Burns, D., Soward, A. C. M., Skelly, A. H., Leeman, J., & Carlson, J. (2008) · The Diabetes Educator · doi:10.1177/0145721708325764 · Cited by 51
Boise, L., Hinton, L., Rosen, H. J., & Ruhl, M. C. (2016) · The Gerontologist · doi:10.1093/geront/gnv683 · Cited by 48 · cited 3×
“demise may affect their willingness in agreeing to brain donations after their death [94].”
BackgroundAdvancing the Science of Recruitment and Retention of Ethnically Diverse Populations
Nápoles, A. M., & Chadiha, L. A. (2011) · The Gerontologist · doi:10.1093/geront/gnr019 · Cited by 48
Strategies for Research Recruitment and Retention of Older Adults of Racial and Ethnic Minorities
McDougall, G. J., Simpson, G. M., & Friend, M. L. (2015) · Journal of Gerontological Nursing · doi:10.3928/00989134-20150325-01 · Cited by 47
The Science of Including Older Ethnic and Racial Group Participants in Health-Related Research
Curry, L., & Jackson, J. (2003) · The Gerontologist · doi:10.1093/geront/43.1.15 · Cited by 45
Self-citationTranslational Research at Community Health Centers
Rosal, M. C., Jo White, M., Borg, A., Scavron, J., Candib, L., Ockene, I., & Magner, R. (2010) · The Diabetes Educator · doi:10.1177/0145721710380146 · Cited by 45
Green-Harris, G., Coley, S. L., Koscik, R. L., Norris, N. C., Houston, S. L., Sager, M. A., Johnson, S. C., & Edwards, D. F. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00125 · Cited by 44
Clement, C., Selman, L. E., Kehoe, P. G., Howden, B., Lane, J. A., & Horwood, J. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190146 · Cited by 42 · cited 7×
“Lastly, AD research recruitment could potentially be facilitated by requesting a patient’s consent to be contacted for eligible research initiatives when they seek medical care at the clinic [61].”
BackgroundInfluentialGalvin, J. E., Meuser, T. M., & Morris, J. C. (2011) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318212c0df · Cited by 41 · cited 2×
“, lost wages, lack of financial compensation) [9, 10, 66, 74–76]; need for frequent medical appointments [10]; lengthy study durations [65]; requirement to undergo repeated diagnostic evaluations [2, 74, 75]; lack of health insurance [75]; lack of adequate transportation [42, 66, 71, 76, 78] Provide flexible appointme…”
BackgroundAndreae, S. J., Halanych, J. H., Cherrington, A., & Safford, M. M. (2012) · Contemporary Clinical Trials · doi:10.1016/j.cct.2012.02.005 · Cited by 40
Realpe, A., Adams, A., Wall, P., Griffin, D., & Donovan, J. L. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.02.002 · Cited by 39 · cited 1×
“or concerns about treatment effectiveness [38] and”
Factors Associated With African American and White Elders' Participation in a Brain Donation Program
Jefferson, A. L., Lambe, S. A., Cook, E., Pimontel, M. A., Palmisano, J. N., & Chaisson, C. E. (2010) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181f3e059 · Cited by 38 · cited 1×
“Unique barriers preventing participation such as mistrust [9, 75, 98]; fear of exploitation [75, 98]; history of racism in research [9, 99]; cultural beliefs surrounding illness [96] as well as medical procedures [98, 99] Establishing rapport with members of diverse communities [98]; Engaging potential research partic…”
BackgroundChange in Cognitive Function in Alzheimer’s Disease in African-American and White Persons
Barnes, L. L., Wilson, R. S., Li, Y., Gilley, D. W., Bennett, D. A., & Evans, D. A. (2005) · Neuroepidemiology · doi:10.1159/000089231 · Cited by 37
Carr, S. A., Davis, R., Spencer, D., Smart, M., Hudson, J., Freeman, S., Cooper, G. E., Schmitt, F. A., Markesbery, W. R., Danner, D. D., et al. (2010) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181aba927 · Cited by 36 · cited 2×
“Provider engagement may also be thwarted by their fear of losing patients to medical research sites [73, 80].”
BackgroundBest strategies to recruit and enroll elderly Blacks into clinical and biomedical research
Graham, L. A., Ngwa, J. S., Ntekim, O. E., Ogunlana, O., Wolday, S., Johnson, S., Johnson, M., Castor, C., Fungwe, T. V., & Obisesan, T. O. (2017) · Clinical Interventions in Aging · doi:10.2147/cia.s130112 · Cited by 35
Grill, J. D., Monsell, S. E., & Karlawish, J. H. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000339361 · Cited by 32 · cited 1×
“AD clinical trials have historically focused on recruiting spouses as study partners [2, 30, 58].”
BackgroundCox, C. G., Mary M. Ryan, B. A., Gillen, D. L., & Grill, J. D. (2018) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2018.10.016 · Cited by 31 · cited 6×
“Furthermore, negative social/emotional implications of labelling an individual with a specific neurodegenerative disorder, typically required for participation in a clinical trial, may also reduce their willingness to enroll in ongoing studies [62].”
BackgroundInfluentialDunbar‐Jacob, J. M., Holmes, J. L., Sereika, S. M., Kwoh, C. K., Burke, L. E., Starz, T. W., McCall, M. K., & Foley, S. M. (2004) · Arthritis Care & Research · doi:10.1002/art.20411 · Cited by 30 · cited 1×
“As such, the clinical trial’s choice of eligibility criteria may unwittingly predetermine the racial composition of the study sample [54, 33], thereby resulting in sampling bias [54].”
BackgroundReasons that prevent the inclusion of Alzheimer's disease patients in clinical trials
Rollin‐Sillaire, A., Breuilh, L., Salleron, J., Bombois, S., Cassagnaud, P., Deramecourt, V., Mackowiak, M., & Pasquier, F. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04423.x · Cited by 28 · cited 3×
“The abovementioned statistic is also especially concerning in light of the evidence that CVD is frequently associated with AD [47, 51] and a significant proportion of AD patients present with vascular abnormalities [47].”
BackgroundCommunity Engagement in Diverse Populations for Alzheimer Disease Prevention Trials
Romero, H., Welsh-Bohmer, K. A., Gwyther, L. P., Edmonds, H. L., Plassman, B. L., GERMAIN, C. M., McCart, M., Hayden, K. M., Pieper, C. F., & Roses, A. D. (2014) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000029 · Cited by 27
Glymour, M. M., & Whitmer, R. A. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190304 · Cited by 26
Factors related to racial differences in late-life level of cognitive function.
Wilson, R. S., Rajan, K. B., Barnes, L. L., Weuve, J., & Evans, D. A. (2016) · Neuropsychology · doi:10.1037/neu0000290 · Cited by 26
Edland, S. D., Emond, J. A., Aisen, P. S. S., & Petersen, R. C. (2010) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181c9983f · Cited by 23
Levy, B., Tsoy, E., & Gable, S. C. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160309 · Cited by 22 · cited 4×
“Unique barriers preventing participation such as mistrust [9, 75, 98]; fear of exploitation [75, 98]; history of racism in research [9, 99]; cultural beliefs surrounding illness [96] as well as medical procedures [98, 99] Establishing rapport with members of diverse communities [98]; Engaging potential research partic…”
BackgroundInfluentialRasouly, H. M., Wynn, J., Marasà, M., Reingold, R. E., Chatterjee, D., Kapoor, S., Piva, S. E., Kil, B. H., Mu, X., Alvarez, M. C., et al. (2019) · Genetics in Medicine · doi:10.1038/s41436-019-0497-y · Cited by 21
Novel recruitment models will drive Alzheimer's trial success
Vidoni, E. D., Bothwell, R. J., Burns, J. M., & Dwyer, J. R. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.10.004 · Cited by 18 · cited 1×
“Unique barriers preventing participation such as mistrust [9, 75, 98]; fear of exploitation [75, 98]; history of racism in research [9, 99]; cultural beliefs surrounding illness [96] as well as medical procedures [98, 99] Establishing rapport with members of diverse communities [98]; Engaging potential research partic…”
BackgroundLora, C. M., Ricardo, A. C., Brecklin, C. S., Fischer, M. J., Rosman, R. T., Carmona-Powell, E., López, A. B., Balaram, M., Nessel, L. C., Tao, K., et al. (2012) · Contemporary Clinical Trials · doi:10.1016/j.cct.2012.07.012 · Cited by 17
Young, L., Montgomery, M., Barnason, S., Schmidt, C., & Do, V. (2015) · GSTF Journal of Nursing and Health Care · doi:10.5176/2010-4804_2.2.71 · Cited by 17 · cited 6×
“Lack of communication between community providers and researchers may limit the provider’s understanding of the study and its potential to benefit their patients [69].”
BackgroundInfluentialHerman, L. M., Atri, A., & Salloway, S. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.001 · Cited by 15
Youn, S. J., Xiao, H., McAleavey, A. A., Scofield, B. E., Pedersen, T. R., Castonguay, L. G., Hayes, J. A., & Locke, B. D. (2018) · Psychotherapy · doi:10.1037/pst0000192 · Cited by 15 · cited 1×
“ment efforts as a clinician champion [73, 86, 87].”
Li, Q., Guo, Y. M., He, Z., Zhang, H., George, T. J., & Bian, J. (2020) · medRxiv · doi:10.1101/2020.08.02.20166629 · Cited by 14 · cited 1×
“suggests a balance between eligibility criteria and safety to expand access to trials in AD [56].”
BackgroundStrategies to enhance recruitment of rural-dwelling older people into community-based trials
Anuruang, S., Davidson, P. M., Jackson, D. W., & Hickman, L. (2015) · Nurse Researcher · doi:10.7748/nr.23.1.40.e1345 · Cited by 14 · cited 1×
“Unique barriers preventing participation such as mistrust [9, 75, 98]; fear of exploitation [75, 98]; history of racism in research [9, 99]; cultural beliefs surrounding illness [96] as well as medical procedures [98, 99] Establishing rapport with members of diverse communities [98]; Engaging potential research partic…”
BackgroundIs it time to use real-world data from primary care in Alzheimer’s disease?
Ponjoan, A., Garre‐Olmo, J., Blanch, J., Fages, E., Alves‐Cabratosa, L., Martí‐Lluch, R., Comas‐Cufí, M., Parramon, D., García-Gil, M., & Ramos, R. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00625-2 · Cited by 13 · cited 2×
“Community-based providers being unaware of ongoing AD clinical trials [2]; lack of communication between community providers and researchers [74]; absence of formal training for referring providers [65]; time constraints experienced by community-based medical providers [78]; fear of losing patients to medical research…”
BackgroundRecruiting Primary Care Practices for Research: Reflections and Reminders
Fernald, D. H., Jortberg, B. T., Hessler, D., Wearner, R., Dickinson, L. M., Fisher, L., & Dickinson, W. P. (2018) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2018.06.180025 · Cited by 12 · cited 1×
“ment efforts as a clinician champion [73, 86, 87].”
Ríos‐Romenets, S., Giraldo, M., López, H., Piedrahita, F., Ramos, C., Acosta‐Baena, N., Muñoz, C., Ospina, P., Tobón, C., Cho, W., et al. (2018) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2017.44 · Cited by 8
Bardach, S. H., Gibson, A., Rhodus, E. K., & Jicha, G. A. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12045 · Cited by 6 · cited 2×
“Caregivers lacking favorable attitudes towards research, fear of potential side-effects, and wish to avoid increasing patient’s burden [9, 10, 66] Provide frequent opportunities to ask clarifying questions [67, 73]; frequent opportunities to discuss risk and benefits of research participation [65]”
BackgroundRecruitment and Retention Strategies for Clinical Trials in Alzheimer’s Disease
Sabbagh, M. N., Thompson, N., Tweedy, D., Stipho-Majeed, S., Kawas, C. H., & Connor, D. J. (2003) · Pharmaceutical Development and Regulation · doi:10.1007/bf03257386 · Cited by 3
Almici, M., Sartori, S., Lombardi, F., Bonomini, C., Geroldi, C., & Zanetti, O. O. (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.04068.x · Cited by 3
Lang, R., Byrd, G. S., Starks, T. D., Som‐Pimpong, D., Phillips, R. G., & Pericak‐Vance, M. A. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.1038 · Cited by 2
P2–301: Use of social media for recruitment in Alzheimer's disease research
Kurtzke, M., Romero, H., & Welsh-Bohmer, K. A. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.949 · Cited by 2
Meelu, O. A., Sartori, S., Theodoropoulos, K. N., Roy, S., Thapi, R., Baber, U., Dangas, G., Moreno, P., Krishnan, P., Kini, A. S., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.08.463 · Cited by 1 · cited 1×
“Comorbid medical and/or psychiatric disturbances Reliance on arbitrary exclusion criteria without adequate accompanying rationale for the same [43–46] Greater transparency in the process of determining appropriate eligibility criteria [43]; revision of exclusion criteria that lack scientific merit [43, 47]; provide de…”
Background
Research works printed but not linked: 8
- Institute of Medicine (US) (2012). The Clinical Trials Process, National Academies Press (US).
- Institute of Medicine (2010) Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary.
- Institute of Medicine (US) (2012) Public Engagement and Clinical Trials: New Models and Disruptive Technologies: Workshop Summary, National Academies Press (US), Washington (DC).
- Evelyn B, 2001, J Natl Med Assoc, 93, 18S
- Seitz DP, 2018, Cochrane Database Syst Rev, 2, CD011415
- ManlyJ, MayeuxR (2004) Ethnic differences in dementia and Alzheimer’s disease. In Critical Perspectives on Racial and Ethnic Differences in Health in Late Life , Anderson NB, Bulatao RA, Cohen B, eds. The National Academies Press, pp. 95–142.
- Assistant Secretary for Planning and Evaluation (2014), Racial and Ethnic Disparities in Alzheimer’s Disease: A Literature Review.
- Boise L, 2017, Gerontologist, 57, 719
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Detection and treatment of Alzheimer’s disease in its preclinical stage
Rafii, M. S., & Aisen, P. S. (2023) · Nature Aging · doi:10.1038/s43587-023-00410-4 · Cited by 160
Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials
Langbaum, J. B. S., Zissimopoulos, J., Au, R., Bose, N., Edgar, C. J., Ehrenberg, E., Fillit, H. M., Hill, C. V., Hughes, L., Irizarry, M. C., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12737 · Cited by 131
Representativeness of samples enrolled in Alzheimer's disease research centers
Rentería, M. A., Mobley, T. M., Evangelista, N. D., Medina, L. D., Deters, K., Fox‐Fuller, J. T., Minto, L. R., Avila‐Rieger, J. F., & Bettcher, B. M. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12450 · Cited by 88
Lim, A. C., Barnes, L. L., Weissberger, G. H., Lamar, M., Nguyen, A. L., Fenton, L. E., Herrera, J., & Han, S. D. (2023) · Communications Medicine · doi:10.1038/s43856-023-00333-6 · Cited by 90
Metadata
- Authors
- Indorewalla, K. K., O’Connor, M. K., Budson, A. E., Guess (DiTerlizzi), C., & Jackson, J.
- Affiliations
- Edith Nourse Rogers Memorial Veterans Hospital (US)
- Boston University (US)
- Boston University Alzheimer’s Disease Research Center, Department of Neurology, Boston University School of Medicine, Boston, MA, USA
- Corresponding author
- Jackson, Jonathan
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2021-02-17
- Volume
- 80
- Issue
- 3
- Pages
- 927-940
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC8150544
- OpenAlex
- W3130554957
- Cited by
- 93
- References
- 101
- Citations by year
- 2026: 15 · 2025: 26 · 2024: 21 · 2023: 20 · 2022: 10 · 2021: 1
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs (I01 CX001698)
- National Institute on Aging (DP1AG069873, P30AG013846)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- participant recruitment
- MeSH terms
- Alzheimer Disease, Clinical Trials as Topic, Humans, Minority Groups, Patient Selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.